Skip to Main Content

Paper Details

Safety and preliminary immunogenicity of JNJ-64041809, a live-attenuated, double-deleted Listeria monocytogenes-based immunotherapy, in metastatic castration-resistant prostate cancer.
Prostate Cancer Prostatic Dis
13
2022
CONCLUSIONS JNJ-809, JNJ-64041809, JNJ-809, LADD, Listeria, Listeria antigen, Listeria monocytogenes, Men, T cell, chills, fatigue, hypertension, interferon-, interleukin-10, intestinal obstruction, listeriolysin O, live-attenuated, double-deleted Listeria, lymphopenia, mCRPC, metastatic castration-resistant prostate cancer, patient, patients, pyrexia, tumor, tumor necrosis factor-
Author NameAffiliation
Russell K PachynskiWashington University of St. Louis
Emmanuel S AntonarakisJohns Hopkins Kimmel Medical Institute
Lawrence FongUCSF Helen Diller Family Comprehensive Cancer Center
  • 1 - 3

Datasets

Release 1.2